TCRX Q3 2022 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$65M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+39.4% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$17M-493.0% margin

Net Income

-$16M-483.1% margin

EPS (Diluted)

$-0.67

QoQ Revenue Growth

-17.1%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$165M

Total Liabilities

$49M

Stockholders' Equity

$117M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+39.4%
Gross Profit	$3M	-$12M	+128.5%
Operating Income	-$17M	-$16M	-4.6%
Net Income	-$16M	-$16M	-2.6%